title: Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma.
abstract: In recent years, more effective and less toxic treatment protocols have been developed to increase the cure rates in intermediate and high grade non-Hodgkin's lymphoma (NHL). This study was undertaken to investigate the efficacy and toxicity of MINE (ifosfamide, mesna, mitoxantrone and etoposide) combination chemotherapy in patients with intermediate and high grade NHL. Twenty-one patients (16 male, 5 female; age between 26 and 70 years) with NHL were included in the study. An overall response rate of 73% and complete response rate of 56% were achieved and survival rate for responding patients was 80% at the 48th month. Side effects including mild myelosuppression, nausea/vomiting and alopecia were observed. MINE combination seems to be effective and well tolerated without significant toxicity as a first-line therapy in patients with intermediate or high grade NHL.
authors.affiliation: Department of Hematology, School of Medicine, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey.
authors.forename: I
authors.initials: I
authors.lastname: Aydogdu
authors.forename: H
authors.initials: H
authors.lastname: Koc
authors.forename: O
authors.initials: O
authors.lastname: Ilhan
authors.forename: G
authors.initials: G
authors.lastname: Gurman
authors.forename: H
authors.initials: H
authors.lastname: Akan
authors.forename: M
authors.initials: M
authors.lastname: Beksac
authors.forename: N
authors.initials: N
authors.lastname: Konuk
authors.forename: A
authors.initials: A
authors.lastname: Uysal
authors.forename: E
authors.initials: E
authors.lastname: Ozerol
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D015080:Mesna / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D008942:Mitoxantrone; D015080:Mesna; D007069:Ifosfamide